Download PDF
Semin Vasc Med 2005; 5(3): 301-307
DOI: 10.1055/s-2005-916170
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Ximelagatran in the Clinic: Practical Management of Patients

Sam Schulman1 , 2 , Gregory Y.H Lip3
  • 1Hamilton Health Sciences-General Hospital, Hamilton, Ontario, Canada
  • 2Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
  • 3University Department of Medicine, City Hospital, Birmingham, United Kingdom
Further Information

Publication History

Publication Date:
25 August 2005 (online)

    Permissions and Reprints

ABSTRACT

Several case studies are briefly introduced, followed by a description of the clinical problem from an epidemiological point of view. The evidence for established management strategies is reviewed and, finally, practical handling of the case is considered.

KEYWORDS

Ximelagatran - orthopedic surgery - anticoagulation management - case studies - venous thromboembolism - atrial fibrillation

REFERENCES

  • 1 Geerts W H, Pineo G F, Heit J A et al.. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 338S-400S
    CrossrefPubMedGoogle Scholar
  • 2 Colwell Jr C W, Spiro T E, Trowbridge A A, Stephens J W, Gardiner Jr G A, Ritter M A. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group.  Clin Orthop. 1995;  321 19-27
    PubMedGoogle Scholar
  • 3 Faunø P, Suomalainen O, Rehnberg V et al.. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin.  J Bone Joint Surg Am. 1994;  76 1814-1818
    PubMedGoogle Scholar
  • 4 Hamulyak K, Lensing A W, vanDer M J, Smid W M, vanOoy A, Hoek J A. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.  Thromb Haemost. 1995;  74 1428-1431
    PubMedGoogle Scholar
  • 5 Heit J A, Berkowitz S D, Bona R et al.. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group.  Thromb Haemost. 1997;  77 32-38
    PubMedGoogle Scholar
  • 6 Leclerc J R, Geerts W H, Desjardins L et al.. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.  Ann Intern Med. 1996;  124 619-626
    PubMedGoogle Scholar
  • 7 Bauer K A, Eriksson B I, Lassen M R, Turpie A G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med. 2001;  345 1305-1310
    CrossrefPubMedGoogle Scholar
  • 8 Francis C W, Berkowitz S D, Comp P C et al.. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.  N Engl J Med. 2003;  349 1703-1712
    CrossrefPubMedGoogle Scholar
  • 9 Colwell C W, Berkowitz S D, Comp P C et al.. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B. [Abstract 39].  Blood. 2003;  102 14
    PubMedGoogle Scholar
  • 10 Eriksson B I, Bergqvist D, Kälebo P et al.. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.  Lancet. 2002;  360 1441-1447
    CrossrefPubMedGoogle Scholar
  • 11 Eriksson B I, Agnelli G, Cohen A T et al.. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.  Thromb Haemost. 2003;  89 288-296
    PubMedGoogle Scholar
  • 12 Dahl O E, Eriksson B I, Agnelli G et al.. Postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery: effects of timing of first dose and risk factors for thromboembolism and bleeding complications on efficacy and safety.  Clinical Drug Investigation. 2005;  25 65-77
    PubMedGoogle Scholar
  • 13 Eriksson B I, Agnelli G, Cohen A T et al.. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.  J Thromb Haemost. 2003;  1 2490-2496
    CrossrefPubMedGoogle Scholar
  • 14 Planes A, Vochelle N, Darmon J Y, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo.  Lancet. 1996;  348 224-228
    CrossrefPubMedGoogle Scholar
  • 15 Dahl O E, Andreassen G, Aspelin T et al.. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin).  Thromb Haemost. 1997;  77 26-31
    PubMedGoogle Scholar
  • 16 Cohen A T, Bailey C S, Alikhan R, Cooper D J. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty-a meta-analysis.  Thromb Haemost. 2001;  85 940-941
    PubMedGoogle Scholar
  • 17 Brandjes D P, Heijboer H, Buller H R, de Rijk M, Jagt H, ten Cate J W. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.  N Engl J Med. 1992;  327 1485-1489
    CrossrefPubMedGoogle Scholar
  • 18 Rosenbeck-Hansen J V, Valdorf-Hansen F, Dige-Petersen H, Hansen W. En kontrolleret undersøgelse af antikoagulationsbehandlingens effekt ved dyb venetrombose og lungeemboli.  Nordisk Med. 1968;  80 1305-1306
    PubMedGoogle Scholar
  • 19 Lagerstedt C I, Olsson C G, Fagher B O, Oqvist B W, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis.  Lancet. 1985;  2 515-518
    PubMedGoogle Scholar
  • 20 Prandoni P, Villalta S, Bagatella P et al.. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.  Haematologica. 1997;  82 423-428
    PubMedGoogle Scholar
  • 21 Hommes D W, Bura A, Mazzolai L, Buller H R, ten Cate J W. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis.  Ann Intern Med. 1992;  116 279-284
    PubMedGoogle Scholar
  • 22 van den Belt A G, Prins M H, Lensing A W et al.. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism (Cochrane Review). In: Update Software. Oxford, UK; The Cochrane Library 2002
    Google Scholar
  • 23 Fiessinger J N, Huisman M V, Davidson B L et al.. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.  JAMA. 2005;  293 681-689
    CrossrefPubMedGoogle Scholar
  • 24 Schulman S, Rhedin A S, Lindmarker P et al.. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.  N Engl J Med. 1995;  332 1661-1665
    CrossrefPubMedGoogle Scholar
  • 25 Pinedé L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel J P. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials.  J Intern Med. 2000;  247 553-562
    CrossrefPubMedGoogle Scholar
  • 26 Büller H R, Agnelli G, Hull R D, Hyers T M, Prins M H, Raskob G E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 401S-428S
    CrossrefPubMedGoogle Scholar
  • 27 van der Heijden J F, Hutten B A, Büller H R, Prins M H. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Review). In: Update Software. Oxford, UK; The Cochrane Library 2002
    Google Scholar
  • 28 Lee A, Julian J A, Levine M N et al.. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism (VTE).  J Thromb Haemost. 2003;  2(Suppl) , OC004 (abstr)
    PubMedGoogle Scholar
  • 29 Hutten B A, Prins M H. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism (Cochrane Review). In: Update Software. Oxford, UK; The Cochrane Library 2002
    Google Scholar
  • 30 Linkins L A, Choi P T, Douketis J D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.  Ann Intern Med. 2003;  139 893-900
    CrossrefPubMedGoogle Scholar
  • 31 Palareti G, Leali N, Coccheri S et al.. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.  Lancet. 1996;  348 423-428
    CrossrefPubMedGoogle Scholar
  • 32 Landefeld C S, Anderson P A, Goodnough L T et al.. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy.  J Clin Epidemiol. 1989;  42 711-718
    CrossrefPubMedGoogle Scholar
  • 33 Levine M N, Raskob G, Beyth R J, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 287S-310S
    CrossrefPubMedGoogle Scholar
  • 34 Schulman S, Wåhlander K, Lundström T, Clason S B, Eriksson H. THRIVE III Investigators . Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.  N Engl J Med. 2003;  349 1713-1721
    CrossrefPubMedGoogle Scholar
  • 35 Wolf P A, Abbott R D, Kannel W B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study.  Arch Intern Med. 1987;  147 1561-1564
    CrossrefPubMedGoogle Scholar
  • 36 Singer D E, Albers G W, Dalen J E, Go A S, Halperin J L, Manning W J. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 429S-456S
    CrossrefPubMedGoogle Scholar
  • 37 van Walraven C, Hart R G, Singer D E et al.. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.  JAMA. 2002;  288 2441-2448
    CrossrefPubMedGoogle Scholar
  • 38 Perez-Gomez F, Alegria E, Berjon J et al.. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.  J Am Coll Cardiol. 2004;  44 1557-1566
    CrossrefPubMedGoogle Scholar
  • 39 Lechat P, Lardoux H, Mallet A et al.. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS).  Cerebrovasc Dis. 2001;  12 245-252
    PubMedGoogle Scholar
  • 40 Olsson S B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.  Lancet. 2003;  362 1691-1698
    CrossrefPubMedGoogle Scholar
  • 41 Albers G W, Diener H C, Frison L et al.. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.  JAMA. 2005;  293 690-698
    CrossrefPubMedGoogle Scholar
  • 42 Lee W M, Larrey D, Olsson R et al.. Hepatic findings in long-term clinical trials of ximelagatran.  Drug Saf. 2005;  28 351-370
    CrossrefPubMedGoogle Scholar
  • 43 Sindet-Pedersen S, Ramström G, Bernvil S, Blombäck M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery.  N Engl J Med. 1989;  320 840-843
    CrossrefPubMedGoogle Scholar